Graphite Bio

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today the presentation of preclinical data for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). Data were presented at the 49th Annual Sickle Cell Disease Association of America (

Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced an abstract related to the company's sickle cell disease (SCD) research has been accepted for poster presentation during the 49th Annual Sickle Cell Disease Association of America (SCDAA) National Convention, taking place virtually Oct.12-16, 2021. Det

Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that members of the management team will participate in virtual fireside chats at the following investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference on Monday, Sept. 13, 2021, at 2:45 p.m. ET; and 2021 Cantor Virtual Global Hea

Graphite Bio Announces Participation in Upcoming September Investor Conferences

Graphite Bio is a clinical-stage development biotech making use of CRISPR-based gene-editing therapy to develop a cure for sickle cell disease. Now, a biotechnology journal has published an adverse report on the safety of CRISPR-Cas9.

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene correction to treat or cure serious diseases, today reported recent business progress and second quarter 2021 financial results. “This has been a transformational period for Graphite Bio as we advance our next-generation gene editing platform to precisely find and replace any gene in the genome. We have built an outstan

Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ:GRPH) just a few weeks after its IPO. BofA Securities on Graphite Bio Analyst Geoff Meacham initiated the firm's coverage on Graphite with a Buy rating and $35 price target.

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share on June 29, 2021. In addition, on June 29, 2021, the underwriters exercised in full their option to pu

Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Graphite Bio Inc (NASDAQ: GRPH) is set to go public on the heels of a $238 million raise less than ten months after getting started with a Series A funding of $45 million.  Graphite is using a familiar tool to tackle genetic diseases with its CRISPR/Cas9 technology.

Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering

Elevation Oncology

GH Research PLC

Mister Car Wash

Alpha Teknova

Acurx Pharmaceuticals LLC

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

7 Companies Go Public Today. What Investors Need to Know.

Graphite Bio Inc. received a warm reception on Wall Street, as the California-based gene-editing biotechnology company's stock opened 30% above its initial public offering price. The IPO priced overnight at $17 a share, at the top of the expected range of between $15 and $17 a share, as the company raised $238 million.

Graphite Bio stock opens 30% above IPO price, pushes valuation above $1 billion

Shares of Graphite Bio Inc. are set to start trading Friday, after the California-based gene-editing biotechnology company's upsized initial public offering priced at the top of the expected range. The company raised $238 million, as it said late Thursday that sold 14.0 million shares in its IPO, which priced at $17 a share.

Graphite Bio stock set to start trading as upsized IPO pricing values biotech at $926.1 million

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Graphite Bio. The gross proceeds to Graphite Bio from the offering, before

Graphite Bio Announces Pricing of Upsized Initial Public Offering

Graphite Bio has filed to raise $200 million in a U.S. IPO of its common stock. The firm is advancing treatments for sickle cell disease and other serious health conditions.

Graphite Bio Finalizes $200 Million IPO Plan

News for Graphite Bio Stock (GRPH)